This episode explores how the EU can tackle the growing burden of non-communicable diseases (NCDs), obesity, and liver health. Featuring Prof. Cyrielle Caussy, the discussion highlights insights from EASL’s recent Brussels event, effective strategies for addressing obesity and other key risk factors, and ways to keep health at the forefront across interconnected sectors such as food, digital, and social policy.
The EASL Policy Dialogues Season 4 is supported by Novo Nordisk. EASL has received no input from Novo Nordisk with regards to the content of the EASL Policy Dialogues Season 4.
Prof. Cyrielle Caussy, Lyon Hepatology Institute, Lyon University, Member of the Governing Board of EASL
Cyrielle Caussy (MD, PhD) is a full Professor of Medicine in Nutrition and an endocrinologist-diabetologist at Lyon 1 University and Hospices Civils de Lyon in France specialized in metabolic diseases. She is also a researcher at CarMen laboratory (Cardio-Metabolism, Diabetes and Nutrition) INSERM U1060. She completed her MD training in 2013 and her PhD in Biochemistry at Lyon 1 University in 2015. Following her fellowship, she completed a 2-year advanced research training at the NAFLD Research Center, University of California at San Diego directed by Pr R. Loomba (2016-2018). Subsequently, she returned to Lyon 1 University as faculty in the department of endocrinology, diabetes and nutrition, Lyon South Hospital at Hospices Civils de Lyon. Currently, she serves as the medical director adjunct of the Rhône-Alpes Research Center for Human Nutrition (CRNH Rhône-Alpes), where she conducts translational and clinical research in Nutrition.
Her academic interests lie in metabolic diseases such as insulin resistance, obesity and type 2 diabetes with a particular focus on steatotic liver disease and MASLD. She leads a clinical and translational research program focusing on metabolic liver disease including multidisciplinary pathway referrals, non-invasive biomarkers and pathophysiology of steatotic liver diseases at the Lyon Hepatology Institute. Furthermore, she co-leads the national AFEF/SFD Liver and Diabetes study group.
